NO20056026L - Kombinert anvendelse av ekteinascidin-743 og platina antineoplastiske forbindelser - Google Patents

Kombinert anvendelse av ekteinascidin-743 og platina antineoplastiske forbindelser

Info

Publication number
NO20056026L
NO20056026L NO20056026A NO20056026A NO20056026L NO 20056026 L NO20056026 L NO 20056026L NO 20056026 A NO20056026 A NO 20056026A NO 20056026 A NO20056026 A NO 20056026A NO 20056026 L NO20056026 L NO 20056026L
Authority
NO
Norway
Prior art keywords
ecteinascidin
combined use
antineoplastic compounds
platinum antineoplastic
platinum
Prior art date
Application number
NO20056026A
Other languages
English (en)
Norwegian (no)
Inventor
Incalci Maurizio D
Luca Gianni
Rafaella Giavazzi
Margarita Garcia Martin
Ian Judson
Donaque Jose Maria Jimeno
Christiana Sessa
Original Assignee
Pharma Mar Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sau filed Critical Pharma Mar Sau
Publication of NO20056026L publication Critical patent/NO20056026L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20056026A 2003-05-29 2005-12-19 Kombinert anvendelse av ekteinascidin-743 og platina antineoplastiske forbindelser NO20056026L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0312407.0A GB0312407D0 (en) 2003-05-29 2003-05-29 Treatment
PCT/GB2004/002319 WO2004105761A1 (en) 2003-05-29 2004-06-01 Combined use of ecteinascidin-743 and platinum antineoplastic compounds

Publications (1)

Publication Number Publication Date
NO20056026L true NO20056026L (no) 2006-02-14

Family

ID=9959022

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056026A NO20056026L (no) 2003-05-29 2005-12-19 Kombinert anvendelse av ekteinascidin-743 og platina antineoplastiske forbindelser

Country Status (15)

Country Link
US (1) US20070128201A1 (ja)
EP (1) EP1635831A1 (ja)
JP (1) JP2007500201A (ja)
KR (1) KR20060015297A (ja)
CN (1) CN1798561A (ja)
AU (1) AU2004243236B2 (ja)
CA (1) CA2525887A1 (ja)
GB (1) GB0312407D0 (ja)
IL (1) IL171942A0 (ja)
NO (1) NO20056026L (ja)
NZ (1) NZ543503A (ja)
RU (1) RU2391101C2 (ja)
UA (1) UA87981C2 (ja)
WO (1) WO2004105761A1 (ja)
ZA (1) ZA200509600B (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
NZ525730A (en) * 2000-11-06 2004-12-24 Pharma Mar S Compositions for antitumour treatments containing Ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
KR20050038578A (ko) * 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
CA2544320A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
ES2308451T3 (es) * 2004-02-18 2008-12-01 Gpc Biotech Ag Satraplatino para el tratamiento de tumores resistentes o refractarios.
WO2006005602A2 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
CZ2004964A3 (cs) * 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
EP1812114A2 (en) * 2004-09-29 2007-08-01 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti-inflammatory agents
DE602005014380D1 (de) * 2004-10-26 2009-06-18 Ortho Biotech Products L P Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743
ES2290844T3 (es) 2004-10-29 2008-02-16 Pharma Mar S.A., Sociedad Unipersonal Composiciones que comprenden ecteinascidinas y un disacarido.
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
EP2205239A2 (en) * 2007-10-29 2010-07-14 Takeda Pharmaceutical Company Limited Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
USD878432S1 (en) 2017-08-23 2020-03-17 Samsung Electronics Co., Ltd. Shelf for refrigerator

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
JP4443043B2 (ja) * 1998-04-06 2010-03-31 ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ 半合成エクテイナシジン
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
CA2418320A1 (en) * 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
NZ525730A (en) * 2000-11-06 2004-12-24 Pharma Mar S Compositions for antitumour treatments containing Ecteinascidin 743
EP1368034A1 (en) * 2001-03-06 2003-12-10 Bristol-Myers Squibb Company Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
KR20050038578A (ko) * 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
CA2544320A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
ES2290844T3 (es) * 2004-10-29 2008-02-16 Pharma Mar S.A., Sociedad Unipersonal Composiciones que comprenden ecteinascidinas y un disacarido.

Also Published As

Publication number Publication date
AU2004243236A1 (en) 2004-12-09
CN1798561A (zh) 2006-07-05
AU2004243236B2 (en) 2010-01-28
CA2525887A1 (en) 2004-12-09
ZA200509600B (en) 2007-02-28
GB0312407D0 (en) 2003-07-02
NZ543503A (en) 2009-11-27
US20070128201A1 (en) 2007-06-07
UA87981C2 (ru) 2009-09-10
EP1635831A1 (en) 2006-03-22
RU2005141408A (ru) 2006-08-10
IL171942A0 (en) 2006-04-10
WO2004105761A1 (en) 2004-12-09
KR20060015297A (ko) 2006-02-16
RU2391101C2 (ru) 2010-06-10
JP2007500201A (ja) 2007-01-11

Similar Documents

Publication Publication Date Title
NO20056026L (no) Kombinert anvendelse av ekteinascidin-743 og platina antineoplastiske forbindelser
LUC00011I2 (ja)
NZ621449A (en) Treatment with anti-vegf antibodies
ATE332136T1 (de) Mittel, wie nikotinamide oder cadpr zur behandlung von hautkrankheiten
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
NO20054988D0 (no) Preparater og metoder for behandling av cancer
AU6155701A (en) Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
SG145695A1 (en) Pyridyl derivatives and their use as therapeutic agents
SG150559A1 (en) Antineoplastic combinations of cci-779 and rituximab
SG145700A1 (en) Pyridyl derivatives and their use as therapeutic agents
IL218317A (en) Use of 15-il polypeptide preparations and 15-il complexes for the preparation of cancer drugs
WO2006050155A3 (en) Cancer therapeutic compositions
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
HK1080447B (zh) 視黃醇衍生物、它們在治療癌症和增强其它細胞毒性劑功效中的應用
HK1105886A1 (en) Pharmaceutical compositions comprising l-733060 for use in the treatment of cancer tumours l-733060
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
JP2006514116A5 (ja)
FR2781153B1 (fr) Composition therapeutique a base de flavonoides destinee a etre utilisee dans le traitement des tumeurs par des agents cytotoxiques
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
MXPA05009849A (es) Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2.
ITVE20140040A1 (it) Materiale per energizzare gli alimenti e per migliorare la prestazione fisica ed il benessere individuale
IL174968A0 (en) The use of ifenprodil in the treatment of pain
TW200615000A (en) Use of arginase for the treatment of hepatitis
DE60004819D1 (de) 10-formyltetrahydrofolate dehydrogenase als therapeutischen mittel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application